ARF has been previously shown to stabilize the epithelial-to-mesenchymal transition (EMT) marker SLUG in prostate cancer [66], while it also regulates the tumor microenvironment through matrix metalloproteinase-7 (MMP7) nuclear translocation [67]. The gene discussed is CDKN2A; the disease is neoplasm.